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Background: Approximately 60% of patients experience moderate-to-severe pain
after neurosurgery, which primarily occurs in the first 24–72 h. Despite this, improved
postoperative analgesia solutions after neurosurgery have not yet been devised. This
retrospective study was conducted to evaluate the effect of intra- and post-operative
infusions of dexmedetomidine (DEX) plus sufentanil on the quality of postoperative
analgesia in patients undergoing neurosurgery.
Methods: One hundred and sixty-three post-neurosurgery patients were divided
into two groups: Group D (DEX infusion at 0.5 µg·kg−1 for 10 min, then adjusted
to 0.3 µg −1 −1·kg ·h until incision suturing) and Group ND (no DEX infusion during
surgery). Patient-controlled analgesia was administered for 72 h after surgery (Group
D: sufentanil 0.02µg −·kg 1·h−1 plus DEX 0.02 1µg·kg−1 −·h , Group ND: sufentanil
0.02 µg kg−1· ·h−1) in this retrospective study. The primary outcome measure was
postoperative sufentanil consumption. Hemodynamics, requirement of narcotic, and
vasoactive drugs, recovery time and the incidence of concerning adverse effects were
recorded. Pain intensity [Visual Analogue Scale (VAS)], Ramsay sedation scale (RSS) and
Bruggemann comfort scale (BCS) were also evaluated at 1, 4, 8, 12, 24, 48, and 72 h
after surgery.
Results: Postoperative sufentanil consumption was significantly lower in Group D
during the first 72 h after surgery (P < 0.05). Compared with Group ND, heart
rate (HR) in Group D was significantly decreased from intubation to 20 min after
arriving at post anesthesia care unit (PACU), while mean arterial pressure (MAP) in
Group D was significantly decreased from intubation to 5min after arriving at PACU
(P < 0.05). The intraoperative requirements for sevoflurane, remifentanil, and fentanyl
were approximately 35% less in Group D compared with Group ND. VAS at rest at
1, 4, and 8 h and with cough at 12, 24, 48, and 72 h after surgery were significantly
lower in Group D (P < 0.05). Compared with Group ND, patients in Group D
showed lower levels of overall incidence of tachycardia, hypertension, nausea, and
vomiting (P < 0.05). There were no significant differences between the two groups
in terms of baseline clinical characteristics, recovery time, RSS, and BCS (P > 0.05).
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Conclusions: DEX (0.02 g kg−1 h−1) plus sufentanil (0.02 g kg−1 1µ · · µ · ·h− ) could reduce
postoperative opioid consumption and concerning adverse adverse effects, while
improving pain scores. However, it did not influence RSS and BCS during the first 72 h
after neurosurgery.
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INTRODUCTION
A previous study reported that 60% of patients experience
moderate-to-severe pain during the first 72 h after neurosurgery
(Flexman et al., 2010). Uncontrolled pain after neurosurgery
may cause adverse events such as hypertension, tachycardia,
and intracerebral hemorrhage, which could prolong hospital
stays, increase medical expenses, and ultimately increase patient
morbidity (Murata et al., 2010).
Bolus or continuous infusions of opioids have been widely
used in patient-controlled analgesia following neurosurgery in
recent decades. However, an increase in analgesic-related side
effects has also been reported (Rozet, 2008; Blaudszun et al.,
2012; Guen et al., 2014; Mariappan et al., 2014). It is a
challenge for anesthesiologists to select a technique that provides
hemodynamic stability, sedation, anxiolysis, and opioid-sparing
and -protective optimal analgesia during the perioperative period
of neurosurgery (Song et al., 2016).
Non-opioid analgesic drugs with opioid-sparing
and -protective effects include N-methyl-d-aspartate antagonists,
gabapentenoids, ketorolac, ketamine, and α2 adrenergic receptor
agonists (Lin et al., 2009; Wu and Raja, 2011; White et al., 2012).
Dexmedetomidine (DEX), a highly selective agonist of the α2
adrenergic receptor, demonstrates a nociceptive-modulating
effect through both the central and spinal cord α2 receptor. It
has a more favorable pharmacokinetic profile than clonidine:
α2:α1 specificity ratio, 1600:1 vs. 200:1, respectively; plasma
half-life T½, 2–2.5 h vs. 9–12 h, respectively; protein binding, 94
vs. 50%, respectively; and a lipophilic action that is 3.5-fold that
of clonidine (Gil et al., 2009). Recent studies have reported that
DEX also has many clinical benefits, such as sedation, analgesia,
and a low risk of significant respiratory depression (Goodwin
et al., 2013; MacLaren et al., 2013). Several studies have shown
that DEX can be used safely for 24 h after craniotomy, but
the sedative and opioid-sparing effects of an intra- and post-
operative infusion of DEX for the first 72 h after neurosurgery
have not been reported (Ho, 2012; Shen et al., 2013; Song et al.,
2016).
The aim of this retrospective study was to observe the opioid-
sparing effect of an intra- and postoperative infusion of DEX and
related adverse events for the first 72 h after neurosurgery.
MATERIALS AND METHODS
Patients
Approval was obtained from the Institutional Review Board of
Liaocheng People’s Hospital and the Fifth People’s Hospital of
Jinan for this retrospective clinical study, which was registered at
chictr.org (ChiCTR-IPR-16008494). Patients provided informed
consent. Patients who underwent neurosurgery from January
2015 to December 2015 were enrolled in this study if they
met the following inclusion criteria: age between 35 and 65
years, American Society of Anesthesiologists (ASA) grade I–
II. Exclusion criteria included a history of endocrinological
disease, hypertension (diastolic blood pressure >160 mmHg),
ischemic heart disease, second or third degree heart block,
pregnancy, long-term abuse of alcohol (>6 months), opioids, or
sedative—hypnotic drugs, DEX allergies, nausea, and vomiting
after previous surgery, neuropsychiatric diseases, operation time
shorter than 1 h or longer than 6 h, blood loss greater than
1200 mL, reoperation during the first 72 h after neurosurgery, or
emergency operation.
Patients were divided into two groups: Group D and Group
ND. A total of 153medical records were reviewed retrospectively,
76 from Group D and 77 from Group ND. Electronic chart and
DoCare clinic electronic anesthesia recording system data were
utilized.
Anesthesia
Electrocardiography, arterial blood pressure, pulse-oximetry,
end-tidal CO2, and temperature were continuously monitored
using an automated system (Philips IntelliVue MP50) after
patients arrived at the operating room, then two peripheral
intravenous catheters were placed in all patients before induction.
A forced-air warming device (EQUATOR Convective Warmer,
EQ-5000) was used in both groups to maintain normothermia.
Patients in Group D received intravenous DEX (0.5 µg·kg−1)
over a period of 10 min before endotracheal intubation,
which was then adjusted to 0.3 µg·kg−1·h−1 until incision
suturing. Both groups were induced using the same agents:
fentanyl (2 µg·kg−1), lidocaine (1.5 mg·kg−1), propofol (2
mg·kg−1), and cisatracurium (0.2 mg·kg−1). General anesthesia
was maintained with a 1–1.2 minimum alveolar concentration
of sevoflurane in an air/oxygen mixture, and a remifentanil
(0.05–0.1 µg·kg−1·min−1) infusion and intermittent boluses of
cisatracurium (0.05 mg·kg−1) for muscle relaxation. Positive
pressure ventilation and oxygenation were maintained with
endotracheal intubation to achieve an arterial partial pressure
of carbon-dioxide of 35–40 mmHg. The concentration of
sevoflurane and rate of remifentanil were adjusted according to
the hemodynamic limits and bispectral Idex. (40–60).
During the operation, bradycardia and tachycardia were
defined as HR < 45 bpm or a >30% increase from baseline
and were treated using atropine (0.2–0.5 mg) or esmolol
(20–30mg), respectively. Hypertension was defined as a >30%
increase from baseline and was treated by increasing the inspired
sevoflurane concentration by 0.2% or remifentanil by 0.02
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µg·kg−1·min−1 in a stepwise titration; fentanyl (1 µg·kg−1)
was used if hypertension was persistent for 3 min, and if
persistent after fentanyl treatment, urapidil (10–15 mg) was
administered. Hypotension was defined as a>30% decrease from
baseline and was treated by decreasing the inspired sevoflurane
concentration by 0.2% or remifentanil by 0.02 µg·kg−1·min−1
in a stepwise titration, and if persistent, by administration of
ephedrine ephedrine (6–12 mg) or phenylephrine (20–80µg).
DEX and sevoflurane were discontinued approximately 15 and 5
min before completion of the surgery, respectively. All patients
received 5mg of tropisetron and underwent routine reversal
of neuromuscular blockade. After extubation in the operating
room, all patients were transferred to the post anesthesia care
unit (PACU).
Postoperative Analgesia Management
Patients in Group ND received sufentanil at a continuous dose
of 0.02µg·kg−1·h−1, a bolus dose of 0.02 µg·kg−1 with a 5-min
lockout interval and a 1 h limit of 16 mL, while patients in Group
D received both sufentanil and DEX under the same regimen as
those in Group ND after arriving at the PACU.
Patients were encouraged to self-control the pump when
they experienced pain during coughing at a severity of Visual
Analogue Scale (VASc) score>4. If patients demonstrated a poor
response to the patient controlled analgesia (PCA) (VASc scores
of >6), or an obvious PCA-associated adverse effect took place,
30mg of ketorolac was administered. If the rescue analgesia was
ineffective 30 min after administration, 100mg of tramadol was
administered.
Data Collection
The intraoperative hemodynamic data (perioperative systolic,
diastolic, mean arterial pressure, and heart rate) were obtained
from the Phillips IntelVue monitor at the following points:
arrival at the operating room (T0), just before intubation (T1),
after intubation (T2), during head pinning (T3), during surgical
incision (T4), extubation (T5), arrival at the PACU (T6), and 5
min (T7), 10 min (T8), 15 min (T9), and 20 min (T10) after
arriving at the PACU. The requirement of narcotic and vasoactive
drugs, fluid requirements, and estimated blood loss, incidence
of complications during the operation and in the PACU were
recorded. The length of the PACU stay was also recorded based
on the Aldretes criteria (Aldrete, 1995).
The cumulative amount of self-administered sufentanil was
recorded until 72 h after the surgery. Postoperative pain intensity
(VAS, both at rest and with cough), the Ramsay Sedation Scale
(RSS: recorded on a six-point scale: 1, subject anxious, agitated, or
restless; 2, subject cooperative, oriented, and tranquil; 3, subject
responds to commands; 4, subject asleep but with brisk response
to light glabellar tap or loud auditory stimulus; 5, subject asleep,
sluggish response to light glabellar tap or loud auditory stimulus;
6, subject asleep, no response), and the Bruggemann comfort
scale (BCS: 0, persistent pain; 1, severe pain while deep breathing
or coughing; 2, mild pain while deep breathing or coughing; 3,
painless while deep breathing; 4, painless while coughing) were
evaluated at 1, 4, 8, 12, 24, 48, and 72 h after surgery. The number
of rescue analgesia and adverse effects (such as bradycardia,
tachycardia, hypotension, hypertension, nausea and vomiting,
agitation, and respiratory depression) was also recorded at the
end of the study.
Statistical Analysis
The data from a preliminary study showed that the requirement
of sufentanil in patients not treated with DEX was approximately
165.34± 23.13µg during the first 72 h after neurosurgery. A 25%
reduction in sufentanil use was considered clinically feasible. For
a study power of 80% (α = 0.05, β = 0.2), assuming a dropout
rate of 15%, the required sample size per group was calculated
to be 75, with a total of 150 patients allowed for adequate data
collection (PASS 11.0, NCSS Statistical Software, Kaysville, Utah).
The Kolmogorov–Smirnov test was used to assess the
distribution of variables. Homogeneity of variance was
determined using Levene’s tests. Quantitative data were
expressed as mean and standard deviation or median and inter-
quartile range. Inter-group comparisons were performed using
repeated-measures analysis of variance. Bonferroni’s correction
was used for post-hocmultiple comparisons. The non-parametric
Wilcoxon—Mann—Whitney test was used for variables that
were not normally distributed. Categorical data were expressed
as frequency and percentage and analyzed using chi-squared tests
or Fisher’s exact tests when appropriate. Probability (P) values
of <0.05 were considered statistically significant. Statistical
analysis was performed using SPSS for Windows Version 18.0
(SPSS Inc., Chicago, IL, USA).
RESULTS
Baseline Characteristics
The patient demographics are illustrated in a patient enrollment
flow diagram (Figure 1). One thousand two hundred and eighty-
three patients who underwent neurosurgery were screened from
January 2015 to December 2015. 1130 patients were excluded
due to not meeting the inclusion criteria: 514 patients required
emergency surgery, 24 patients refused the surgery, the age
of 143 patients did not fall in the specified range of 35–65
years, the ASA grade of 72 patients was more than II, 129
patients had cardiovascular and neuropsychiatric diseases, 35
patients had a long history of addiction to alcohol, opioids and
sedative–hypnotic drugs, 78 patients had nausea and vomiting
after previous surgery, the operation time of 67 patients was
longer than 6 h, 35 patients demonstrated hemorrhage of more
than 1200mL, 23 patients required reoperation during the first
72 h after neurosurgery, three patients refused use the PCA after
surgery, and seven patients were excluded after surgery due to
incomplete clinical data. Finally, 153 patients were included in
the primary analysis and divided into two groups (76 patients in
Group D and 77 patients in Group ND).
The two groups were comparable regarding age, sex, BMI,
ASA grade, history of comorbidity and tumor location (Table 1).
Intraoperative Variables
Baseline HR andMAP were not statistically different between the
two groups (P > 0.05; Figure 2). Compared with Group ND, HR
in Group D was significantly decreased from T1 to T10, while
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FIGURE 1 | Patient enrolment flow diagram.
MAP in Group D was significantly decreased from T1 to T7
(P < 0.05; Figure 2). The lowest levels of HR and MAP of the
two groups were observed at T1.
Compared with Group ND, the consumption of sevoflurane
[1.38 ± 0.42 vs. 1.04 ± 0.35 minimum alveolar concentration
(MAC), P < 0.001], remifentail (0.13 ± 0.03 vs. 0.19 ± 0.05
µg·kg−1·min−1, P < 0.01), fentanyl (3.24 ± 1.13 vs. 4.72 ± 1.41
µg·kg−1 P < 0.01) and estimated blood loss (486.57 ± 33.38
vs. 505.04 ± 32.52ml, P < 0.01) were significantly decreased
in Group D (P < 0.05, Table 2). More patients in Group ND
than in Group D required an intraoperative vasoactive agent:
urapidil (32 vs. 21, respectively, P = 0.01), phenylephrine (17 vs.
7, respectively, P = 0.03) and esmolol (37 vs. 25, respectively,
P = 0.01), while the requirements for ephedrine (6 vs. 5,
respectively, P = 1.00) and atropine (8 vs. 9, respectively, P
= 0.06) were similar (Tables 3, 4). There were no statistically
significant differences between the two groups in terms of
duration of surgery and anesthesia, infusion, and urine output,
with the exception of recovery time at the PACU (27.72 ± 3.78
vs. 45.14± 4.29min; P > 0.05; Table 2).
Postoperative Variables
The total dosage and dosage per body weight of sufentanil were
significantly lower in Group D than in Group ND at 4, 8, 12,
24, 48, and 72 h after surgery (P < 0.05, Figure 3). Compared
with Group ND, the VAS scores at rest at 1, 4, and 8 h after
surgery and with cough at 12, 24, 48, and 72 h after surgery were
significantly lower in Group D (P < 0.05, Figure 4). In Group
D, 11 patients (14.47%) required postoperative rescue analgesia,
while 21 patients (29.87%) required rescue analgesia in Group
ND (P = 0.02, Table 5). There were no significant differences
between the two groups in terms of RSS and BCS during the first
72 h after neurosurgery (P > 0.05, Figure 5).
The main adverse events are recorded in Table 5. Patients in
Group D showed a lower incidence of tachycardia (6 vs. 15, P
= 0.04), hypertension (12 vs. 28, P = 0.02), delirium (6 vs. 19,
P = 0.01), nausea (12 vs. 27, P = 0.01) and vomiting (5 vs.
14, P = 0.01) than patients in Group ND. However, there are
no statistically significant differences between the two groups in
terms of the incidence of bradycardia (3 vs. 5, P = 0.28) and
hypotension (7 vs. 11, P = 0.42). Although more patients in
Group ND suffered seizures during the period of this study than
those in Group D, the difference was not statistically significant
(P = 0.49, Table 6).
DISCUSSION
In this retrospective trial DEX plus sufentanil (0.02 µg·kg−1·h−1,
each) as PCA in patients who underwent neurosurgery could
decrease both the total dosage and dosage per body weight of
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TABLE 1 | Demographics data of patients in the two groups.
Group D (n = 76) Group ND (n = 77) P-values
Age (years) 51.35 ± 8.34 49.55 ± 7.69 0.17
Body weight (kg) 67.45 ± 7.23 68.67 ± 4.64 0.13
Height (m) 1.63 ± 0.25 1.64 ± 0.27 0.81
BMI (kg·m−2 ) 22.24 ± 2.46 22.05 ± 1.98 0.60
Sex (male/female) 45/31 50/27 0.47
ASA I to II (n) 12/64 19/58 0.17
TUMOR lOCATION, n (%)
Frontal 35 (46.05%) 36 (46.75%) 0.92
Occipital 6 (7.89%) 7 (9.09%)
Parietal 22 (31.58%) 20 (25.97%)
Temporal 13 (14.47%) 14 (18.18%)
COMORBIDITY, n (%)
Hypertension 30 (39.47%) 28 (36.36%) 0.32
Arrhythmia 12 (15.79%) 13 (16.88%)
Diabetes mellitus 9 (11.84%) 8 (10.39%)
COPD/asthma 6 (7.89%) 5 (6.49%)
Anemia 5 (6.58%) 6 (7.79%)
Variables presented as mean ± SD or number of patients n (%). Group D, sufentanil
0.02 µg·kg−1·h−1 plus dexmedetomidine 0.02 µg·kg−1·h−1; Group ND, sufentanil 0.02
µg·kg−1·h−1; BMI, body mass index; ASA, American Society of Anesthesiology; COPD,
chronic obstructive pulmonary disease.
sufentanil from 4 to 72 h after surgery and improve postoperative
analgesia during the 72 h after surgery. It was also found that
HR and MAP; the requirement of sevoflurane, remifentanil,
and fentanyl; and the estimated blood loss were significantly
decreased in Group D during the operation (P < 0.05). VAS at
rest at 1, 4, and 8 h and with cough at 12, 24, 48, and 72 h
after surgery were significantly lower in Group D than in Group
ND (P < 0.05). More patients in Group ND required urapidil,
phenylephrine, and esmolol during surgery and postoperative
rescue analgesia (P < 0.05). However, there were no significant
differences between the two groups in terms of baseline clinical
characteristics, RSS, BCS, and main adverse events with the
exception of tachycardia, hypertension, delirium, nausea, and
vomiting.
The challenge facing neuroanesthesiologists is how to select
a technique that provides sedation, anxiolysis and analgesia
during surgery while minimizing hemodynamic instability and
concerning adverse effects. Hemodynamic stability after surgery
is vital for patients, especially in those with comorbidities
such as hypertension, arrhythmia and diabetes (Amadori et al.,
2013). Although opioids, anesthetics, and antihypertensive drugs
are routinely used to maintain hemodynamic stability during
the perioperative period, concerning adverse effects such as
hypotension, bradycardia, nausea, vomiting, and respiratory
depression as a result of overcompensation still arise. Several
anesthetic techniques have been reported recently to solve this
problem, however an ideal solution has not been reported so far
(Osborn and Sebeo, 2010; Bekker et al., 2013; Akeju et al., 2014;
Seemann et al., 2015; Goettel et al., 2016). Asleep-awake-asleep
(AWA) is an available option for ASA I–II patients, in addition
to general anesthesia (GA), commonly used in neurosurgery,
FIGURE 2 | Hemodynamics were monitored in the two groups.
TABLE 2 | Intraoperative data of patients in the two groups.
Group D Group ND P-values
(n = 76) (n = 77)
Duration of surgery (min) 199.75±35.81 209.73± 43.02 0.12
Duration of anesthesia (min) 223.21±34.19 230.64± 37.36 0.20
Estimated blood loss (mL) 486.57±33.38 505.04± 32.52* 0.00
Fluids (mL) 2266.72±321.66 2325.62± 297.62 0.24
Urine output (mL) 727.25±136.37 689.72± 143.56 0.10
Sevoflurane (MAC) 1.38±0.42 1.04± 0.35* 0.00
Remifentail dosage
(µg·kg−1·min−1 )
0.13±0.03 0.19± 0.05* 0.00
Fentanyl dosage (µg·kg−1 ) 3.24±1.13 4.72± 1.41* 0.00
Cisatracurium dosage
(mg·kg−1·h−1 )
0.16±0.03 0.15± 0.05 0.14
Recovery time at PACU (min) 27.72±3.78 45.14± 4.29* 0.00
Variables presented as mean ± SD or number of patients n (%). Group D, sufentanil
0.02 µg·kg−1·h−1 plus dexmedetomidine 0.02 µg·kg−1·h−1; Group ND, sufentanil 0.02
µg·kg−1·h−1; MAC, minimum alveolar concentration. PACU, post anesthesia anesthesia
care unit. *P < 0.05 vs. Group D.
which requires intraoperative monitoring. The hallmark of AWA
is to provide adequate analgesia and sedation in patients who are
required to be cooperative during the surgery (Deiner andHagen,
2009; Seemann et al., 2015).
Only patients under GA were recruited in this retrospective
study, because hemodynamic instability has been reported to be
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TABLE 3 | The consumption of vasoactive drugs during surgery.
Group D (n = 76) Group ND (n = 77) P-values
Atropine 8 (10.53%) 9 (11.69%) 0.06
Esmolol 37 (48.68%) 25 (32.47%)* 0.01
Ephedrine 6 (7.89%) 5 (6.49%) 1.00
Phenylephrine 17 (22.37%) 7 (9.09%)* 0.03
Urapidil 32 (42.11%) 21 (27.27%)* 0.01
Variables presented as mean ± SD or number of patients n (%). Group D, sufentanil
0.02 µg·kg−1·h−1 plus dexmedetomidine 0.02 µg·kg−1·h−1; Group ND, sufentanil 0.02
µg·kg−1·h−1. *P < 0.05 vs. Group D.
TABLE 4 | The pharmacotherapies of vasoactive drugs.
Action site Metabolism t1/2
Atropine M-cholinoceptor Hepatic enzyme 3.7–4.3 h
Esmolol β1-adrenergic receptor Esterase (erythrocytic
cytoplasm)
9min
Ephedrine adrenergic receptor Kidney 3–6 h
Phenylephrine α-adrenergic receptor Monoamine oxidase 4–8min
Urapidil α1-adrenergic receptor Kidney 2.7 h
more common in AWA patients (Deras et al., 2012). Bekker
et al. first reported that DEX could be used safely in patients
undergoing awake craniotomy (Bekker et al., 2001). Following
studies evaluated the influence of DEX on the ability to perform
neurocognitive testing during neurosurgery, but the results were
not consistent (Mack et al., 2004; Santos and Vinagre, 2006).
Uyar et al. reported that a single bolus dose of DEX before
induction of anesthesia could attenuate the hemodynamic and
neuroendocrine responses to skull-pin insertion (Uyar et al.,
2008). The manufacturer of DEX recommends a bolus infusion
of 1.0 µg·kg−1 over 10 min before induction, followed by a
maintenance infusion of 0.2–0.7 µg·kg−1·h−1 until 20–30 min
before the end of surgery (Afonso and Reis, 2012). However, a
previous study has reported that intraoperative administration
of DEX with a smaller bolus and a lower maintenance infusion
could offer greater hemodynamic stability during neurosurgery
(Sturaitis et al., 2002). On the basis of previously published
literature and standard treatment in our center, patients in Group
ND received intravenous DEX at 0.5 µg·kg−1 over a period of 10
min before endotracheal intubation, which was then adjusted to
0.3 µg·kg−1·h−1 until incision suturing. As a result, it was found
that compared with Group ND, both HR and MAP in Group D
were significantly decreased during the neurosurgery (P < 0.05).
At the same time, the number of patients in Group Dwho needed
urapidil, phenylephrine, and esmolol was significantly decreased
(P< 0.05). A potential explanation is the better effect of the DEX-
opioid combination used in Group D during neurosurgery in
terms of sympathetic response and antinociceptive properties, as
previous studies have shown that DEX demonstrates nociceptive-
modulating effects through both the central and spinal cord α2
receptor without significant respiratory depression (Gil et al.,
2009; Goodwin et al., 2013; MacLaren et al., 2013).
FIGURE 3 | Postoperative consumption of PCA sufentanil in the two
groups.
For a long time, craniotomy was thought to be less
painful than other surgical procedures. The perioperative pain
management of patients undergoing neurosurgery has drawn
more attention recently, and an increasing number of studies
have reported that most patients experience moderate-to-severe
pain after neurosurgery (Gottschalk et al., 2007; Flexman et al.,
2010; Blaudszun et al., 2012; Schnabel et al., 2013). Although
it is generally known that poorly controlled pain after surgery
could translate into chronic pain which might influence long-
term quality of life, neurosurgeons are still generally reluctant
to treat it adequately because of concerns about respiratory and
cerebral depression (Peng et al., 2014). Morphine is the most
commonly used opioid for postoperative pain as it is economical
and easy to manage. Meta-analyses have reported the benefits
of using sufentanil, especially with respect to adverse effects.
However, nausea, vomiting, and respiratory depression have
also been reported as a result of overcompensation (Pöpping
et al., 2012; Youssef et al., 2014). A multimodal analgesia that
could enhance analgesia and reduce the requirement for opioids
would be productive. Previous studies conducted by this research
group have found that the use of DEX-sufentanil for 72 h after
surgery could offer better analgesic effects and patient satisfaction
compared with sufentanil alone (Ren et al., 2015a,b). In this
study, the dosage of sufentanil was significantly lower in Group
D compared with Group ND from 4 to 72 h after surgery
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FIGURE 4 | Time course of postoperative pain [at rest/with cough]
expressed as scores on a visual analogue scale (VAS) out of 10 in the
two groups.
(P < 0.05). Compared with Group ND, the analgesic effect was
better in Group D. However, significant differences between the
two groups in terms of RSS and BCS during the first 72 h after
surgery were not observed (P > 0.05).
Previous studies have found that the most common side
effects associated with DEX are bradycardia and hypotension
(Bekker et al., 2013; Guen et al., 2014; Zhang et al., 2014).
However, in this study, the overall incidence of bradycardia
and hypotension was not significantly different between the
two groups. A possible explanation for this difference is that a
relatively lower dose was used for both bolus and continuous
infusion than previous studies and the recommendations of the
DEX manufacturer (Guen et al., 2014; Zhang et al., 2014). The
incidence of nausea and vomiting was lower in Group D, partly
because of the lower dose of sufentanil used for postoperative
analgesia. Because of the advantages of DEX in terms of
cardiovascular stability and protective effects on neurocognitive
function, more patients in Group ND developed complications
such as tachycardia (P = 0.04), hypertension (P = 0.02), and
delirium (P = 0.01).
We acknowledge that the present study has some limitations.
First, this study is a retrospective trial, and a multi-center large
sample prospective study is necessary to more rigorously verify
the feasibility of DEX-sufentanil treatment for postoperative
FIGURE 5 | Comparison of patient sedation (Ramsay sedation scale
[RSS]) and patient satisfaction (Bruggemann comfort scale [BCS])
between the two groups.
TABLE 5 | Patients requiring rescue analgesia during the 72h after surgery
in Group D and Group ND.
Group D (n = 76) Group ND (n = 77) P-values
n (%) 11 (14.47%) 23 (29.87%)* 0.02
Variables presented as number of patients n (%). Group D, sufentanil 0.02 µg·kg−1·h−1
plus dexmedetomidine 0.02 µg·kg−1·h−1; Group ND, sufentanil 0.02 µg·kg−1·h−1.
*P < 0.05 vs. Group D.
TABLE 6 | Postoperative adverse events of patients in Groups D and ND.
Group D (n = 76) Group ND (n = 77) P-values
Nausea 12 (15.79%) 27 (35.06%)* 0.01
Vomiting 5 (6.58%) 14 (18.18%)* 0.01
Tachycardia 6 (7.89%) 15 (19.48%)* 0.04
Bradycardia 3 (3.95%) 5 (6.49%) 0.28
Hypertension 12 (15.80%) 28 (36.37%)* 0.02
Hypotension 7 (9.21%) 11 (14.29%) 0.42
Seizure 4 (5.26%) 5 (6.49%) 0.49
Delirium 6 (7.89%) 19 (24.68%)* 0.01
Variables presented as mean ± SD or number of patients n (%). Group D, sufentanil
0.02 µg·kg−1·h−1 plus dexmedetomidine 0.02 µg·kg−1·h−1; Group ND, sufentanil 0.02
µg·kg−1·h−1. *P < 0.05 vs. Group D.
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analgesia. Second, operation time varies according to the type
of surgical procedure; however, the duration of surgery and
anesthesia was not significantly different between the two
groups. Third, DEX was administered at a rate of 0.5 µg·kg−1
for 10 min before intubation and then at a rate of 0.3
µg·kg−1·h−1 during the operation until incision suturing. The
serum concentration of DEX was not measured in this study
as a result of technical limitations and increasing costs. Fourth,
no patients were found to experience respiratory depression.
This could be because all patients were transferred to an
intensive care unit to be observed for at least 24 h and a
lower dose of DEX and sufentanil was used for postoperative
analgesia. Finally, this trial only studied one dosage of DEX-
sufentanil (0.02µg·kg−1·h−1, each) after neurosurgery, and
different dosages of DEX-sufentanil should be be further
investigated.
In summary, to our best knowledge, this is the first report
regarding the application of DEX (0.02 µg·kg−1·h−1) plus
sufentanil (0.02 µg·kg−1·h−1), which could reduce postoperative
sufentanil consumption and improve pain scores, while not
improving RSS and BCS scores during the first 72 h after
neurosurgery. However, more multi-center prospective studies
are still required to determine the optimal dosage of DEX-
sufentanil to be applied during the perioperative period of
neurosurgery.
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